Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Completed · Phase 3
Conditions studied: Multiple Sclerosis, Relapsing-Remitting
In brief
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).
Key facts
- Study ID
- NCT02555215
- Run by
- Biogen
- People needed
- 20
- Starts
- 2016-02-22
- Expected to finish
- 2018-09-24
- Last updated by the study team
- 2019-11-22
Who can join
Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Loma Linda, California, United States
- Research Site — Ghent, Belgium
- Research Site — Sofia, Bulgaria
- Research Site — Hradec Králové, Czechia
- Research Site — Munich, Bavaria, Germany
- Research Site — Göttingen, Lower Saxony, Germany
- Research Site — Kuwait City, Kuwait
- Research Site — Riga, Latvia
- Research Site — Beirut, Lebanon
- Research Site — Gdansk, Poland
- Research Site — Poznan, Poland
- Research Site — Ankara, Turkey (Türkiye)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.